SINTX Technologies, Inc.

As of March 29, 2023, SINTX Technologies, Inc. is rated as risky due to overvaluation and poor financial metrics, including a negative P/E ratio of -1.6293, despite a recent strong 1-month return of 32.70%, which still underperformed compared to the S&P 500's 2.33% return.

As of March 29, 2023, SINTX Technologies, Inc. is classified as "risky" and overvalued, with poor financial metrics including a Price to Book Value of 1.17, a negative ROCE of -822.40%, and a one-year return of -45.66%, significantly underperforming the S&P 500.

As of June 10, 2025, SINTX Technologies, Inc. shows a neutral technical trend with mixed signals, indicating a shift from mildly bearish to sideways, as weekly indicators suggest mild bullishness while daily moving averages lean bearish.

As of March 2022, the management team of SINTX Technologies, Inc. is led by Dr. B. Sonny Bal, who is the Chairman, President, CEO, and CFO, alongside independent directors Mr. Mark Froimson, Mr. Eric Stookey, Mr. David Truetzel, and Mr. Jeffrey White.

SINTX Technologies, Inc. is a biomaterial company specializing in silicon nitride orthopedic medical devices. As of March 2025, it reported net sales of $0 million and a net loss of $2 million, with a market cap of $8.38 million.

As of Jun 18, SINTX Technologies, Inc. has a market capitalization of 8.38 million, with net sales of 2.57 million and a net profit of -12.43 million over the latest four quarters. Shareholder's funds are 3.89 million, and total assets amount to 9.41 million.